Effects of PKC412, nilotinib and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity: Mutant PDGFRA: PKC412, nilotinib, imatinib

類似資料

• Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias
  著者:: Weisberg, Ellen, 等
  出版事項: (2007)
• Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412
  著者:: Growney, Joseph D., 等
  出版事項: (2005)
• Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
  著者:: Weisberg, Ellen, 等
  出版事項: (2008)
• Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
  著者:: Cauchi, C., 等
  出版事項: (2011)
• Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
  著者:: Sako, Hiroyuki, 等
  出版事項: (2014)